{ "responseHeader":{ "status":0, "QTime":0, "params":{ "q":"iati_identifier:GB-COH-03877777-F328401", "fl":"*", "format":"json" } }, "response":{ "numFound":1, "start":0, "numFoundExact":true, "docs":[{ "last-updated-datetime":"2025-03-05T04:21:49Z", "last_updated_datetime":"Wed Mar 05 04:21:49 UTC 2025", "last_updated_datetime_f":"2025-03-05T04:21:49Z", "lang":"en", "default_lang":"en", "default-currency":"USD", "default_currency":"USD", "humanitarian":false, "hierarchy":1, "iati-identifier":"GB-COH-03877777-F328401", "iati_identifier":"GB-COH-03877777-F328401", "reporting-org.type":"15", "reporting_org_type_code":"15", "reporting-org.ref":"GB-COH-03877777", "reporting_org_ref":"GB-COH-03877777", "reporting-org.secondary-reporter":false, "reporting_org_secondary_reporter":"0", "reporting-org.narrative":[" British International Investment plc"], "reporting_org_narrative":[" British International Investment plc"], "reporting-org.narrative.lang":["en"], "title.narrative":["Kelix Bio Limited"], "title_narrative":["Kelix Bio Limited"], "title_narrative_text":["Kelix Bio Limited"], "title.narrative.lang":[" "], "title_narrative_lang":[" "], "description.type":["1","4"], "description_type":["1","4"], "description.narrative":["Kelix Bio (formerly Zanzibar Pharma) is a specialty generic pharmaceuticals business focused on emerging markets. The company aims to develop and commercialise affordable products in countries historically deprived of access to such medications.","Direct Equity"], "description_narrative":["Kelix Bio (formerly Zanzibar Pharma) is a specialty generic pharmaceuticals business focused on emerging markets. The company aims to develop and commercialise affordable products in countries historically deprived of access to such medications.","Direct Equity"], "description_narrative_text":["Kelix Bio (formerly Zanzibar Pharma) is a specialty generic pharmaceuticals business focused on emerging markets. The company aims to develop and commercialise affordable products in countries historically deprived of access to such medications.","Direct Equity"], "description.narrative.lang":[" "," "], "description_narrative_lang":[" "," "], "participating-org.ref":["GB-COH-03877777"], "participating_org_ref":["GB-COH-03877777"], "participating-org.type":["15"], "participating_org_type":["15"], "participating-org.role":["1"], "participating_org_role":["1"], "participating-org.narrative":["British International Investment plc"], "participating_org_narrative":["British International Investment plc"], "participating_org_narrative_text":["British International Investment plc"], "participating-org.narrative.lang":[" "], "participating_org_narrative_lang":[" "], "activity-status.code":"2", "activity_status_code":"2", "activity-date.type":["2","1"], "activity_date_type":["2","1"], "activity-date.iso-date":["2022-01-21T00:00:00Z","2022-01-21T00:00:00Z"], "activity_date_iso_date":["2022-01-21T00:00:00Z","2022-01-21T00:00:00Z"], "recipient-country.code":["EG"], "recipient_country_code":["EG"], "recipient-region.code":["189"], "recipient_region_code":["189"], "recipient-region.percentage":[100.0], "recipient_region_percentage":[100.0], "recipient-region.vocabulary":["1"], "recipient_region_vocabulary":["1"], "sector.code":["12220"], "sector_code":["12220"], "sector.vocabulary":["1"], "sector_vocabulary":["1"], "collaboration-type.code":"6", "collaboration_type_code":"6", "default-flow-type.code":"10", "default_flow_type_code":"10", "default-aid-type.code":["C01"], "default_aid_type":["C01"], "default_aid_type_category_code":["C01"], "default_aid_type_code":["C01"], "default-aid-type.vocabulary":["1"], "default_aid_type_vocabulary":["1"], "default-tied-status.code":"5", "default_tied_status_code":"5", "transaction.transaction-type.code":["2"], "transaction_type":["2"], "transaction.transaction-date.iso-date":["2022-01-21T00:00:00Z"], "transaction_date_iso_date":["2022-01-21T00:00:00Z"], "transaction.value":[3.694945315E7], "transaction_value":[3.694945315E7], "transaction.description.narrative":["We invested $100 million into a specialised pharmaceuticals platform to address the constrained availability of high-quality medicines throughout Africa due to the lack of competition. We joined with Development Partners International, and the European Bank for Reconstruction and Development to bring together an Egyptian pharmaceuticals manufacturer with an Indian generic drugs company to create a new platform to introduce lower cost generic drugs into Egypt, and then on the African continent. Together, the three founding investors have committed an initial $250 million of capital that has been used to fund the acquisition and combination of the two companies.In 2022 we made a further investment of $50 million into the platform to continue support its expansion in Africa via the acquisition of a Moroccan generics manufacturer, Pharmaceutical Institute. The three founding investors have committed a total of $200 million in this second round of capital raise."], "transaction_description_narrative":["We invested $100 million into a specialised pharmaceuticals platform to address the constrained availability of high-quality medicines throughout Africa due to the lack of competition. We joined with Development Partners International, and the European Bank for Reconstruction and Development to bring together an Egyptian pharmaceuticals manufacturer with an Indian generic drugs company to create a new platform to introduce lower cost generic drugs into Egypt, and then on the African continent. Together, the three founding investors have committed an initial $250 million of capital that has been used to fund the acquisition and combination of the two companies.In 2022 we made a further investment of $50 million into the platform to continue support its expansion in Africa via the acquisition of a Moroccan generics manufacturer, Pharmaceutical Institute. The three founding investors have committed a total of $200 million in this second round of capital raise."], "transaction.description.narrative.lang":[" "], "transaction_description_lang":[" "], "transaction.provider-org.ref":["GB-COH-03877777"], "transaction_provider_org_ref":["GB-COH-03877777"], "transaction.provider-org.provider-activity-id":["GB-COH-03877777"], "transaction_provider_org_provider_activity_id":["GB-COH-03877777"], "transaction.provider-org.type":["70"], "transaction_provider_org_type":["70"], "transaction.provider-org.narrative":["British International Investment plc"], "transaction_provider_org_narrative":["British International Investment plc"], "transaction_provider_org_narrative_text":["British International Investment plc"], "transaction.provider-org.narrative.lang":[" "], "transaction_provider_org_narrative_lang":[" "], "transaction.receiver-org.narrative":["Kelix Bio Limited"], "transaction_receiver_org_narrative":["Kelix Bio Limited"], "transaction_receiver_org_narrative_text":["Kelix Bio Limited"], "transaction.receiver-org.narrative.lang":[" "], "transaction_receiver_org_narrative_lang":[" "], "transaction.value.value-date":["2022-01-21T00:00:00Z"], "transaction_value_date":["2022-01-21T00:00:00Z"], "reporting-org.type.name":"Other Public Sector", "reporting_org_type_name":"Other Public Sector", "recipient-country.name":["Egypt"], "recipient_country_name":["Egypt"], "recipient-region.name":["North of Sahara, regional"], "recipient_region_name":["North of Sahara, regional"], "default-aid-type.name":["Project-type interventions"], "default_aid_type_category_name":["Project-type interventions"], "title.narrative.first":"Kelix Bio Limited", "title_narrative_first":"Kelix Bio Limited", "activity-date.start-actual":"2022-01-21T00:00:00Z", "activity_date_start_actual":"Fri Jan 21 00:00:00 UTC 2022", "activity_date_start_actual_f":"2022-01-21T00:00:00Z", "activity-date.common.start":"2022-01-21T00:00:00Z", "activity_date_start_common":"Fri Jan 21 00:00:00 UTC 2022", "activity_date_start_common_f":"2022-01-21T00:00:00Z", "activity-date.start-planned":"2022-01-21T00:00:00Z", "activity_date_start_planned":"Fri Jan 21 00:00:00 UTC 2022", "activity_date_start_planned_f":"2022-01-21T00:00:00Z", "activity-status.text":"Implementation", "activity_status_text":"Implementation", "transaction.value-usd.sum":3.694945315E7, "transaction_value_usd_sum":3.694945315E7, "transaction.value-usd.conversion-rate":[1.0], "transaction_usd_conversion_rate":[1.0], "transaction.value-usd.conversion-currency":["USD"], "transaction.value-gbp.sum":2.72741496688351E7, "transaction_value_gbp_sum":2.72741496688351E7, "transaction.value-gbp.conversion-rate":[1.354742626209917], "transaction_gbp_conversion_rate":[1.354742626209917], "transaction.value-gbp.conversion-currency":["USD"], "dataset.id":"7e4b5f6f-a12c-4a85-b555-e63f75af07b5", "dataset_iati_id":"7e4b5f6f-a12c-4a85-b555-e63f75af07b5", "dataset.name":"bii-activities", "dataset_name":"bii-activities", "dataset.extras.iati_version":"2.03", "dataset.resources.hash":"45892ebb68e2a1f3ed94b9d52c4bb262558a46e3", "dataset.resources.url":"https://aidstream.s3.us-west-2.amazonaws.com/xml/bii-activities.xml", "activity-date.quarter":[1,1], "transaction.transaction-date.quarter":[1], "transaction.value-usd":[3.694945315E7], "transaction_value_usd":[3.694945315E7], "transaction.value-usd-type":[2], "transaction.value-gbp":[2.72741496688351E7], "transaction_value_gbp":[2.72741496688351E7], "transaction.value-gbp-type":[2], "activity-aggregation.outgoing-commitment.value":3.694945315E7, "activity_aggregation_commitment_value":3.694945315E7, "activity-aggregation.outgoing-commitment.value-usd":3.694945315E7, "activity_aggregation_commitment_value_usd":3.694945315E7, "activity-aggregation.outgoing-commitment.value-gbp":2.72741496688351E7, "activity_aggregation_commitment_value_gbp":2.72741496688351E7, "json.reporting-org":"{\"type\": 15, \"ref\": \"GB-COH-03877777\", \"secondary-reporter\": 0, \"narrative\": \" British International Investment plc\", \"narrative.lang\": \"en\"}", "json.title":"{\"narrative\": \"Kelix Bio Limited\", \"narrative.lang\": \" \"}", "json.description":["{\"type\": 1, \"narrative\": \"Kelix Bio (formerly Zanzibar Pharma) is a specialty generic pharmaceuticals business focused on emerging markets. The company aims to develop and commercialise affordable products in countries historically deprived of access to such medications.\", \"narrative.lang\": \" \"}","{\"type\": 4, \"narrative\": \"Direct Equity\", \"narrative.lang\": \" \"}"], "json.participating-org":["{\"ref\": \"GB-COH-03877777\", \"type\": 15, \"role\": 1, \"narrative\": \"British International Investment plc\", \"narrative.lang\": \" \"}"], "json.activity-date":["{\"type\": 2, \"iso-date\": \"2022-01-21\"}","{\"type\": 1, \"iso-date\": \"2022-01-21\"}"], "json.recipient-country":["{\"code\": \"EG\"}"], "json.recipient-region":["{\"code\": 189, \"percentage\": 100, \"vocabulary\": 1}"], "json.sector":["{\"code\": 12220, \"vocabulary\": 1}"], "json.default-aid-type":["{\"code\": \"C01\", \"vocabulary\": 1}"], "json.transaction":["{\"transaction-type\": {\"code\": 2}, \"transaction-date\": {\"iso-date\": \"2022-01-21\"}, \"value\": 36949453.15, \"description\": {\"narrative\": \"We invested $100 million into a specialised pharmaceuticals platform to address the constrained availability of high-quality medicines throughout Africa due to the lack of competition. We joined with Development Partners International, and the European Bank for Reconstruction and Development to bring together an Egyptian pharmaceuticals manufacturer with an Indian generic drugs company to create a new platform to introduce lower cost generic drugs into Egypt, and then on the African continent. Together, the three founding investors have committed an initial $250 million of capital that has been used to fund the acquisition and combination of the two companies.In 2022 we made a further investment of $50 million into the platform to continue support its expansion in Africa via the acquisition of a Moroccan generics manufacturer, Pharmaceutical Institute. The three founding investors have committed a total of $200 million in this second round of capital raise.\", \"narrative.lang\": \" \"}, \"provider-org\": {\"ref\": \"GB-COH-03877777\", \"provider-activity-id\": \"GB-COH-03877777\", \"type\": 70, \"narrative\": \"British International Investment plc\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"narrative\": \"Kelix Bio Limited\", \"narrative.lang\": \" \"}, \"value.value-date\": \"2022-01-21\"}"], "id":"716ca5e2-1064-4d4e-a1a6-8ea5c059962c", "_version_":1863489637103697920 }] } }